MX2023001492A - Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. - Google Patents
Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.Info
- Publication number
- MX2023001492A MX2023001492A MX2023001492A MX2023001492A MX2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A
- Authority
- MX
- Mexico
- Prior art keywords
- fatigue
- subject
- inflammatory cytokines
- mediated disease
- complement mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5428—IL-10
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/306—Chronic fatigue syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062243P | 2020-08-06 | 2020-08-06 | |
| PCT/US2021/044761 WO2022031978A1 (en) | 2020-08-06 | 2021-08-05 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001492A true MX2023001492A (es) | 2023-03-08 |
Family
ID=77750323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001492A MX2023001492A (es) | 2020-08-06 | 2021-08-05 | Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230357433A1 (enExample) |
| EP (1) | EP4193153A1 (enExample) |
| JP (1) | JP2023536904A (enExample) |
| KR (1) | KR20230044312A (enExample) |
| CN (1) | CN116724236A (enExample) |
| AU (1) | AU2021320870A1 (enExample) |
| BR (1) | BR112023001942A2 (enExample) |
| CA (1) | CA3187866A1 (enExample) |
| IL (1) | IL300376A (enExample) |
| MX (1) | MX2023001492A (enExample) |
| WO (1) | WO2022031978A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| WO2022212645A1 (en) * | 2021-03-31 | 2022-10-06 | Bioverativ Usa Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
| US20240117021A1 (en) * | 2022-06-15 | 2024-04-11 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| CA3260415A1 (en) * | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| CA2981321A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| MX2017016835A (es) * | 2015-06-26 | 2018-08-01 | Bioverativ Usa Inc | Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. |
| US11464810B2 (en) * | 2016-08-25 | 2022-10-11 | California Institute Of Technology | Ascaroside treatment of eosinophilic esophagitis |
| CN110300520B (zh) * | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| CR20190468A (es) | 2017-03-14 | 2019-12-17 | Bioverativ Usa Inc | Métodos para tratar enfermedades y trastornos mediados por completo |
| EP3774892A4 (en) * | 2018-04-13 | 2022-02-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE |
| JP7499760B2 (ja) * | 2018-11-02 | 2024-06-14 | アネクソン，インコーポレーテッド | 脳損傷を治療するための組成物及び方法 |
-
2021
- 2021-08-05 IL IL300376A patent/IL300376A/en unknown
- 2021-08-05 BR BR112023001942A patent/BR112023001942A2/pt unknown
- 2021-08-05 MX MX2023001492A patent/MX2023001492A/es unknown
- 2021-08-05 CN CN202180056699.1A patent/CN116724236A/zh active Pending
- 2021-08-05 KR KR1020237007908A patent/KR20230044312A/ko active Pending
- 2021-08-05 AU AU2021320870A patent/AU2021320870A1/en active Pending
- 2021-08-05 JP JP2023507563A patent/JP2023536904A/ja active Pending
- 2021-08-05 WO PCT/US2021/044761 patent/WO2022031978A1/en not_active Ceased
- 2021-08-05 EP EP21770091.3A patent/EP4193153A1/en active Pending
- 2021-08-05 CA CA3187866A patent/CA3187866A1/en active Pending
-
2023
- 2023-02-03 US US18/164,521 patent/US20230357433A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4193153A1 (en) | 2023-06-14 |
| KR20230044312A (ko) | 2023-04-03 |
| US20230357433A1 (en) | 2023-11-09 |
| WO2022031978A1 (en) | 2022-02-10 |
| IL300376A (en) | 2023-04-01 |
| CA3187866A1 (en) | 2022-02-10 |
| AU2021320870A1 (en) | 2023-04-06 |
| CN116724236A (zh) | 2023-09-08 |
| JP2023536904A (ja) | 2023-08-30 |
| BR112023001942A2 (pt) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001492A (es) | Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| MX2023009831A (es) | Metodos y sistemas para mejorar la condicion dermica. | |
| MX2022010224A (es) | Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. | |
| PH12022550167A1 (en) | High concentration anti-c5 formulations | |
| CO2019001246A2 (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
| BR112022002837A2 (pt) | Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo | |
| WO2019008123A3 (en) | CELLS, VERTEBRATES, POPULATIONS AND METHODS | |
| MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| HK1250238A1 (zh) | 抗angptl8抗体及其用途 | |
| MX2022015248A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| PH12019502857A1 (en) | Il-1 beta binding antibodies for use in treating cancer | |
| MA45125B1 (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MX2023003519A (es) | Anticuerpo anti-semaforina 4d humano. | |
| PH12022550450A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| MX2022003668A (es) | Metodos y composiciones para el tratamiento de la retinopatia diabetica. | |
| MX2021009586A (es) | Metodo de determinacion de condiciones de configuracion para instalaciones de fabricacion, metodo de determinacion del valor de configuracion de molino para molino de laminado, dispositivo de determinacion del valor de configuracion de molino para molino de laminado, metodo de fabricacion de productos y metodo de fabricacion de material laminado. | |
| PH12020550409A1 (en) | Anti-trkb monoclonal antibodies and methods of use | |
| MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
| MX2022015959A (es) | Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| WO2016168344A8 (en) | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features | |
| ZA202305072B (en) | Cd1a antibodies and uses thereof | |
| MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
| PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof |